Spironolactone showed no significant benefit in reducing the composite of cardiovascular mortality and heart failure ...

The trial enrolled just half of its planned patients, leaving spironolactone’s role in HFpEF and HFmrEF still up in the air.

Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension ...

NEW YORK -- An old cardiovascular drug has emerged as a key option for hormonal management of acne -- with recognized safety caveats. Studies dating back to the 1980s have demonstrated the efficacy of ...

A trial testing the aldosterone blocker spironolactone in patients with heart failure with preserved ejection fraction (HFpEF ...

The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart attack or stroke. More ...

Spironolactone use among young women and girls has been growing since 2000 for acne and other androgen-related conditions. Although established for cardiovascular indications, spironolactone is not ...

Studies have shown that routine monitoring for hyperkalemia has limited usefulness, says Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston.

As the global prevalence of hypertension increases, healthcare providers are caring for patients for whom standard antihypertensive therapy is failing. This dilemma often occurs in patients who are on ...

Please provide your email address to receive an email when new articles are posted on . While the level of evidence was generally low, spironolactone was not associated with statistically significant ...